What is the cure rate for aplastic anemia?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 20, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Cure Rates for Aplastic Anemia

Aplastic anemia is highly curable with appropriate treatment, achieving long-term survival rates of 80-90% in most patients, with cure rates reaching up to 90% in young patients receiving matched sibling donor transplantation 1.

Age-Dependent Cure Rates

The curability of aplastic anemia varies significantly by age and treatment modality:

Young Patients (<40 years)

  • Matched sibling donor hematopoietic cell transplantation (HCT): 80-90% disease-free survival, with children under 10 years having especially superior outcomes 1
  • Young adults (20-40 years): 80-90% probability of disease-free survival after matched sibling HCT 1
  • Children with matched sibling donors: 79% cure rate with allogeneic bone marrow transplantation 2

Older Patients (>40 years)

  • Overall long-term survival: >80-90% with modern supportive care improvements 1
  • For this age group, immunosuppressive therapy (IST) is preferred over HCT due to higher transplant-related risks 1

Treatment-Specific Outcomes

Hematopoietic Cell Transplantation

  • Matched sibling donors: Up to 90% cure rate 3, with 80% cure rates in recent studies 4
  • Unrelated donors: 70% cure rate 4, with 37% survival in CD34+ enriched, partially T-cell depleted transplants 3
  • Cord blood: Emerging as a newer stem cell source 3

Immunosuppressive Therapy

  • Overall response rate: 70-80% hematological response 5
  • Complete remission: 25-55% depending on the study 2, 6
  • 5-year survival in responders: 80-90% 3
  • Relapse rate: Approximately 10% 3

Important Caveats

A critical pitfall is that "cure" differs between treatment modalities: HCT offers true cure with disease-free survival, while IST achieves remission but carries risks of relapse (10%) and clonal evolution to paroxysmal nocturnal hemoglobinuria or myelodysplastic syndrome 5.

Recent improvements in supportive care have dramatically improved outcomes: In recent decades, treatment-related mortality has decreased considerably with either HCT or IST, resulting in >80-90% long-term survivors 1.

Without treatment, outcomes are dismal: Supportive care alone results in 75% mortality with very short survival times 2, emphasizing the importance of definitive therapy.

Treatment Selection Algorithm

The 2026 ASH guidelines provide clear direction 1:

  1. Age <40 years with matched sibling donor available: HCT is first-line treatment
  2. Age >40 years: IST is preferred over HCT, even with matched sibling donor available
  3. No matched sibling donor: IST with consideration of unrelated donor HCT as second-line after IST failure
  4. Modern IST regimens: Include eltrombopag addition to improve outcomes 1

The overall message is optimistic: with appropriate treatment selection based on age and donor availability, the vast majority of aplastic anemia patients can expect long-term survival or cure.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.